TCR² Therapeutics Inc.

TCR² Therapeutics Inc.
TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit
Location: United States, Massachusetts, Cambridge
Member count: 51-200
Total raised: $125M
Founded date: 2015

Investors 6

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
21.03.2018Series B$

Mentions in press and media 7

20.01.2021TCR² Thera...---mpmcapital...
31.12.2018Next-gen T...Patrick Baeuer­le Patrick Bae...FinancingNatalie
22.03.2018Term Sheet...THE VC WAR CHEST Good
21.03.2018TCR2 Thera... CAMBRIDGE, MA, Immuno-oncolo...--vcnewsdail...
21.03.2018MPM Portfo...---mpmcapital...
21.03.2018TCR2 Thera...TCR2 Therapeutics Inc., an imm...--citybizlis...
21.03.2018TCR2 Thera...TCR2 Therapeutics Inc., a